BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 34638541)

  • 21. Chronic oxymatrine treatment induces resistance and epithelial‑mesenchymal transition through targeting the long non-coding RNA MALAT1 in colorectal cancer cells.
    Xiong Y; Wang J; Zhu H; Liu L; Jiang Y
    Oncol Rep; 2018 Mar; 39(3):967-976. PubMed ID: 29328404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Stromal POSTN induced by TGF-β1 facilitates the migration and invasion of ovarian cancer.
    Yue H; Li W; Chen R; Wang J; Lu X; Li J
    Gynecol Oncol; 2021 Feb; 160(2):530-538. PubMed ID: 33317907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long non-coding RNA CCAT1 promotes metastasis and poor prognosis in epithelial ovarian cancer.
    Cao Y; Shi H; Ren F; Jia Y; Zhang R
    Exp Cell Res; 2017 Oct; 359(1):185-194. PubMed ID: 28754469
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long non-coding RNA AOC4P suppresses epithelial ovarian cancer metastasis by regulating epithelial-mesenchymal transition.
    Lin X; Tang X; Zheng T; Qiu J; Hua K
    J Ovarian Res; 2020 Apr; 13(1):45. PubMed ID: 32334623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MALAT1/miR-124/Capn4 axis regulates proliferation, invasion and EMT in nasopharyngeal carcinoma cells.
    Shi B; Wang Y; Yin F
    Cancer Biol Ther; 2017 Oct; 18(10):792-800. PubMed ID: 28857668
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma.
    Chen S; Wu DD; Sang XB; Wang LL; Zong ZH; Sun KX; Liu BL; Zhao Y
    Cell Death Dis; 2017 Oct; 8(10):e3118. PubMed ID: 29022892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of long non-coding RNA XIST has anticancer effects on epithelial ovarian cancer cells through inverse downregulation of hsa-miR-214-3p.
    Wang C; Qi S; Xie C; Li C; Wang P; Liu D
    J Gynecol Oncol; 2018 Nov; 29(6):e99. PubMed ID: 30207107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long non-coding RNA GClnc1 knockdown suppresses progression of epithelial ovarian cancer by recruiting FOXC2 to disrupt the NOTCH1/NF-κB/Snail pathway.
    Wu D; Ke Y; Xiao R; Liu J; Li Q; Wang Y
    Exp Cell Res; 2021 Feb; 399(1):112422. PubMed ID: 33338479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. DPY30 is required for the enhanced proliferation, motility and epithelial-mesenchymal transition of epithelial ovarian cancer cells.
    Zhang L; Zhang S; Li A; Zhang A; Zhang S; Chen L
    Int J Mol Med; 2018 Dec; 42(6):3065-3072. PubMed ID: 30221689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer.
    Zhou X; Hu Y; Dai L; Wang Y; Zhou J; Wang W; Di W; Qiu L
    PLoS One; 2014; 9(5):e96718. PubMed ID: 24816687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Silencing of the long noncoding RNA LINC01132 alleviates the oncogenicity of epithelial ovarian cancer by regulating the microRNA‑431‑5p/SOX9 axis.
    Zhu W; Xiao X; Chen J
    Int J Mol Med; 2021 Aug; 48(2):. PubMed ID: 34132375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Up-regulation of long intergenic noncoding RNA 01296 in ovarian cancer impacts invasion, apoptosis and cell cycle distribution via regulating EMT.
    Xu H; Zheng JF; Hou CZ; Li Y; Liu PS
    Cell Signal; 2019 Oct; 62():109341. PubMed ID: 31176022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.
    Zhang J; Liu L; Sun Y; Xiang J; Zhou D; Wang L; Xu H; Yang X; Du N; Zhang M; Yan Q; Xi X
    Oncotarget; 2016 May; 7(18):26516-34. PubMed ID: 27049921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway.
    Zhao J; Liu HR
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3243-3252. PubMed ID: 31081076
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer.
    Biamonte F; Santamaria G; Sacco A; Perrone FM; Di Cello A; Battaglia AM; Salatino A; Di Vito A; Aversa I; Venturella R; Zullo F; Costanzo F
    Sci Rep; 2019 Apr; 9(1):5668. PubMed ID: 30952937
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long noncoding RNA FTX promotes epithelial-mesenchymal transition of epithelial ovarian cancer through modulating miR-7515/TPD52 and activating Met/Akt/mTOR.
    Li Y; Zhu X; Zhang C; Yin Y; Chen L; Liu Y; He A; Xia F
    Histol Histopathol; 2023 Dec; 38(12):1487-1498. PubMed ID: 37140169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
    Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
    Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
    [TBL] [Abstract][Full Text] [Related]  

  • 39. LINC00968 accelerates the progression of epithelial ovarian cancer via mediating the cell cycle progression.
    Yao N; Sun JQ; Yu L; Ma L; Guo BQ
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4642-4649. PubMed ID: 31210289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long non-coding RNA SNHG1 stimulates ovarian cancer progression by modulating expression of miR-454 and ZEB1.
    Wu Y; Zhu B; Yan Y; Bai S; Kang H; Zhang J; Ma W; Gao Y; Hui B; Li R; Zhang X; Ren J
    Mol Oncol; 2021 May; 15(5):1584-1596. PubMed ID: 33641229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.